Pharmaceuticals News and Research

RSS

Novo Growth Equity invests in Orexo

Orexo AB and Novo A/S today announced combined transactions encompassing a directed new issue by Orexo of a SEK 111 million convertible bond to Denmark-based Novo A/S and the acquisition of significant blocks of existing shares by Novo A/S from two existing venture capital shareholders, subject to approval at an Extraordinary General Meeting. The conversion price of the convertible bonds is set at 25 per cent premium to the closing share price on 12 March, 2010.

15 Mar 2010

Patheon's first-quarter fiscal 2010 total revenues up 5.2%

Patheon a global provider of drug development and manufacturing services to the international pharmaceutical industry today announced results for its first quarter ended January 31, 2010. All amounts are in U.S. dollars unless otherwise indicated.

15 Mar 2010

BioSante Pharmaceuticals receives receipt of Orphan Drug designation for GVAX Pancreas Vaccine

BioSante Pharmaceuticals, Inc. today announced BioSante’s receipt of Orphan Drug designation from the FDA’s Office of Orphan Products Development for GVAX Pancreas Vaccine in the treatment of pancreatic cancer.

15 Mar 2010

Alnylam Pharmaceuticals presents data on RNAi therapeutic targeting PCSK9 for hypercholesterolemia

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today the presentation of new pre-clinical data from its hypercholesterolemia program, performed in collaboration with scientists at the University of Texas Southwestern Medical Center at Dallas. The data were presented at the PCSK9 Conference: From Gene to Therapeutics held in Nantes, France from March 11-13, 2010.

15 Mar 2010

iGPS urges the U.S. Senate to mandate latest tracking technology in legislation to prevent foodborne illnesses

Cost-effective technology that allows products to be traced through the U.S. supply chain might have helped contain the spread of hydrolyzed vegetable protein products contaminated with Salmonella, Intelligent Global Pooling Systems announced today. iGPS urged the U.S. Senate to mandate the latest tracking technology in legislation pending to overhaul the nation's food safety law.

15 Mar 2010

Insmed posts net profit of $2.3M for fourth-quarter 2009

Insmed Inc., a biopharmaceutical company, today reported results for the fourth quarter and full-year ended December 31, 2009.

15 Mar 2010

StockPreacher.com announces investment report featuring GenVec

StockPreacher.com announces an investment report featuring GenVec Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

15 Mar 2010

Inspire Pharmaceuticals reports results of two AZASITE Phase 2 clinical trials for blepharitis

Inspire Pharmaceuticals, Inc. announced today the results from two Phase 2 clinical trials with AZASITE (azithromycin ophthalmic solution) 1% for the treatment of blepharitis. Inspire will conduct additional clinical work to continue pursuing a potential indication for treatment of anterior and posterior forms of blepharitis.

15 Mar 2010

American Oriental Bioengineering's fiscal 2009 revenues up 11.9%

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced financial results for the fourth quarter and fiscal year ended December 31, 2009.

15 Mar 2010

Matrix signs MOU with PharmaVentures

Matrix Corporate Capital and PharmaVentures Limited today announced the signing of a Memorandum of Understanding ("MOU") covering strategic transactions in the biotech, pharmaceutical and med tech sectors. The companies will work together to identify licensing, buyout, investment, IPO and consolidation opportunities which bring together both strategic expertise and capital from Europe's dedicated healthcare investors.

15 Mar 2010

Rhythm Pharmaceuticals completes $21M Series A equity financing

Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that it has completed the first close on its Series A equity financing of $21 million. The financing was led by MPM Capital and New Enterprise Associates. The funds will be used to develop products licensed from Ipsen.

15 Mar 2010

Researchers discover microtentacles that play key role in spreading cancer to distant locations in body

Researchers at the University of Maryland Marlene and Stewart Greenebaum Cancer Center have discovered that "microtentacles," or extensions of the plasma membrane of breast cancer cells, appear to play a key role in how cancers spread to distant locations in the body. Targeting these microtentacles might prove to be a new way to prevent or slow the growth of these secondary cancers, the scientists say.

15 Mar 2010

NDA for BYDUREON: FDA issues complete response letter

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration has issued a complete response letter regarding the New Drug Application for BYDUREON™ (exenatide for extended-release injectable suspension).

15 Mar 2010

A.P. Pharma reports net loss of $1.9M for fourth-quarter of 2009

A.P. Pharma, Inc., a specialty pharmaceutical company, today reported financial results for its fourth quarter and full year ended December 31, 2009.

15 Mar 2010

Data from ACCORD Lipid study: Abbott issues statement

Results were presented today on behalf of the National Heart, Lung and Blood Institute from ACCORD, a study in patients with diabetes that evaluated cardiovascular outcomes in three distinct studies – glycemic control, blood pressure control and lipid control.

15 Mar 2010

U.S. prescribing information for PLAVIX revised

Sanofi-aventis U.S. and Bristol-Myers Squibb Company today announced revisions to the U.S. prescribing information for PLAVIX® (clopidogrel bisulfate), which include a boxed warning. The boxed warning concerns the diminished effectiveness of PLAVIX in patients who have a genetic variation leading to reduced formation of the active metabolite.

15 Mar 2010

Sigma-Aldrich and Pfizer sign new agreement

Sigma-Aldrich® today announced that it has entered into an agreement with Pfizer under which Sigma-Aldrich will sell approximately 100 Pfizer-developed small molecule compounds to life science researchers for target characterization, assay development, screening and in vivo animal model applications.

15 Mar 2010

New PEGylated Polylysine dendrimers: Benefits patients with cancer, HIV and lymphatic conditions

Monash Institute of Pharmaceutical Science researchers, in collaboration with the biotechnology company Starpharma Holdings Ltd have developed a new method to deliver medications that may benefit thousands of patients with particular types of cancer, HIV and lymphatic conditions world-wide.

15 Mar 2010

AAPHP urges FDA to reclassify electronic cigarette as tobacco product

The American Association of Public Health Physicians submitted a petition to the US Food and Drug Administration on February 23rd in response to their official stance concerning electronic cigarettes.

15 Mar 2010

Orexigen Therapeutics, Patheon sign long-term agreement for commercial manufacturing of Contrave

Orexigen® Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, and Patheon Inc., a global provider of drug development and manufacturing services, announced today a long-term agreement for commercial manufacturing of Contrave® (naltrexone HCL sustained release (SR)/bupropion HCL SR) as well as development of future formulations of Orexigen products.

15 Mar 2010